Researchers Find Link Between Carbapenems and Superinfections & CDI
JUN 01, 2017 | CONTAGION® EDITORIAL STAFF
Khalid Eljaaly, PharmD, MS, CAPPS, BCPS, Contagion Editorial Advisory Board member, postdoctoral research fellow on infectious diseases and antimicrobial stewardship, the University of Arizona, College of Pharmacy, explains his team’s findings on the link between carbapenems and superinfections & Clostridium difficile.
Interview Transcript (slightly modified for readability)
“Carbapenem antibiotics are very valuable agents because they have broad spectrum of activity, allowing us to treat several infections including multidrug-resistant organisms.
We did a meta-analysis of randomized clinical trials of patients with pneumonia that compared any of the meropenem or imipenem versus other antibiotics. We found that carbapenems actually cause more superinfections and [Clostridium difficile infections].
Before starting this meta-analysis, there [was an established] link between giving broad spectrum antibiotics and superinfections and C. diff. This is most likely because when you give broad spectrum antibiotics, you [will] inhibit normal microflora and its ecological balance in humans. [This leads] to overgrowth of opportunistic organisms and superinfection.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512